For the year ending 2025-12-31, KAPA had $3,219K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Proceeds from common stock issued for cash in connection with the closing of the initial public offering | 0 |
| Proceeds from notes payable - officers | 0 |
| Payment of deferred offering costs | 0 |
| Proceeds from the sale and exercise of prefunded warrants | 3,058 |
| Proceeds from the equity line of credit | 3,602 |
| Net cash provided by financing activities | 6,660 |
| Debt discount amortization | 0 |
| Fair value of common shares issued in connection with the conversion of accounts payable | 0 |
| Fair value of warrants issued in connection with convertible notes payable | 0 |
| Gain on settlement of accounts payable | 0 |
| Vendor advances | 0 |
| Amortization of vendor advances | 2,170 |
| Fair value of vested restricted stock units | 482 |
| Prepaid expenses and other current assets | 13 |
| Accounts payable and accrued expenses | -793 |
| Net loss | -5,447 |
| Amortization of intangible asset | 160 |
| Net cash used in operating activities | -3,441 |
| Net increase in cash and cash equivalents | 3,219 |
| Net increase in cash and cash equivalents | 3,219 |
| Cash and cash equivalents, beginning of period | 1,272 |
| Cash and cash equivalents, end of period | 4,491 |
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)